Literature DB >> 8623466

Pharmacokinetics of mycophenolate mofetil (RS61443): a short review.

R E Bullingham1, A Nicholls, M Hale.   

Abstract

Overall, the PK of MMF is reasonably straightforward and relatively unaffected by the complex pathophysiological changes involved in the management of renal transplant recipients. The ability to relate plasma MPA concentrations to efficacy through the PK/PD correlation implies that, unlike for many other drugs, plasma PK has direct relevance to the clinical outcome. These features should not only greatly help the exploration of immunosuppressive regiments using MMF but also the development of clinical use of MMF in situations other than renal transplantation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8623466

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  41 in total

Review 1.  Therapeutic drug monitoring of immunosuppressant drugs.

Authors:  A Johnston; D W Holt
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

Review 2.  Clinical mycophenolic acid monitoring in liver transplant recipients.

Authors:  Hao Chen; Bing Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients.

Authors:  Hao Chen; Chenghong Peng; Zhicheng Yu; Baiyong Shen; Xiaxing Deng; Weihua Qiu; Yue Fei; Chuan Shen; Guangwen Zhou; Weiping Yang; Hongwei Li
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  The occurrence of diarrhea not related to the pharmacokinetics of MPA and its metabolites in liver transplant patients.

Authors:  Zhang Wei Xia; Chen Yong Jun; Chen Hao; Chen Bing; Shi Min Min; Xie Jun Jie
Journal:  Eur J Clin Pharmacol       Date:  2010-05-15       Impact factor: 2.953

6.  Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine.

Authors:  Satoshi Hibino; Takuhito Nagai; Satoshi Yamakawa; Hidekazu Ito; Kazuki Tanaka; Osamu Uemura
Journal:  Clin Exp Nephrol       Date:  2016-04-22       Impact factor: 2.801

Review 7.  The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy.

Authors:  Guido Filler; Ana Catalina Alvarez-Elías; Christopher McIntyre; Mara Medeiros
Journal:  Pediatr Nephrol       Date:  2016-02-26       Impact factor: 3.714

8.  Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant.

Authors:  Bronwyn A Atcheson; Paul J Taylor; David W Mudge; David W Johnson; Carmel M Hawley; Scott B Campbell; Nicole M Isbel; Peter I Pillans; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

9.  Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.

Authors:  Laurent R Chiarelli; Mariadelfina Molinaro; Carmelo Libetta; Carmine Tinelli; Laura Cosmai; Giovanna Valentini; Antonio Dal Canton; Mario Regazzi
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

10.  Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.

Authors:  Zheng Jiao; Jun-Jie Ding; Jie Shen; Hui-Qi Liang; Long-Jin Zhong; Yi Wang; Ming-Kang Zhong; Wei-Yue Lu
Journal:  Br J Clin Pharmacol       Date:  2008-02-15       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.